# SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population

> **NCT07051603** · PHASE1 · RECRUITING · sponsor: **Shenzhen Salubris Pharmaceuticals Co., Ltd.** · enrollment: 82 (estimated)

## Conditions studied

- Uncontrolled Hypertension

## Interventions

- **DRUG:** SAL0140
- **DRUG:** SAL0140 placebo

## Key facts

- **NCT ID:** NCT07051603
- **Lead sponsor:** Shenzhen Salubris Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-09
- **Primary completion:** 2026-01
- **Final completion:** 2026-02
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2025-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07051603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07051603, "SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07051603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*